Alimentary Tract| Volume 49, ISSUE 12, P1327-1331, December 2017

Download started.


Acute histological inflammatory activity is associated with clinical relapse in patients with ulcerative colitis in clinical and endoscopic remission

Published:September 08, 2017DOI:



      It has been suggested that acute histological activity has a prognostic value in the outcome of ulcerative colitis (UC) patients in clinical and endoscopic remission. Our aim was to assess the role of histology as a risk factor for clinical relapse (CR) in patients in both clinical and endoscopic remission.


      Patients with left-sided or extensive UC in clinical and endoscopic remission (Mayo endoscopic subscore ≤1) undergoing colonoscopy for dysplasia surveillance with random colonic biopsies between 2005–2015 were included. Basal plasmacytosis, acute (AHA), and the chronic (CHA) histological inflammatory activity of all biopsy sets were evaluated.


      One hundred and thirteen patients were included. Median time in clinical remission at inclusion was 27 months (IQR 15–56). Eight percent of patients relapsed within the first year and 33% during the whole follow-up period. In the univariate analysis, the presence of AHA, alone (P = 0.048) or together with a past flare within the previous 12 months (P = 0.01), was associated with CR within the first year of follow-up. In the multivariate analysis, AHA, together with a flare within the previous 12 months, remained the only risk factor for relapse (RR = 7.5; IC95%; 1.8–29.9; P = 0.005).


      In UC patients in clinical and endoscopic remission, the presence of AHA is a risk factor for clinical relapse.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ordás I.
        • Eckmann L.
        • Talamini M.
        • Baumgart D.C.
        • Sandborn W.J.
        Ulcerative colitis.
        Lancet. 2012; 380: 1606-1619
        • Pineton de Chambrun G.
        • Blanc P.
        • Peyrin-Biroulet L.
        Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.
        Expert Rev Gastroenterol Hepatol. 2016; 10: 915-927
        • Rosenberg L.
        • Lawlor G.O.
        • Zenlea T.
        • Goldsmith J.D.
        • Gifford A.
        • Falchuk K.R.
        • et al.
        Predictors of Endoscopic Inflammation in Patients With Ulcerative Colitis in Clinical Remission.
        Inflamm Bowel Dis. 2013; 19: 779-784
        • Colombel J.-F.
        • Keir M.E.
        • Scherl A.
        • Zhao R.
        • de Hertogh G.
        • Faubion W.A.
        • et al.
        Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC.
        Gut. 2016; 0 (312307. [Epub ahead of print]): 1-6
        • Guardiola J.
        • Lobatón T.
        • Rodríguez-Alonso L.
        • Ruiz-Cerulla A.
        • Arajol C.
        • Loayza C.
        • et al.
        Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission.
        Clin Gastroenterol Hepatol. 2014; 12: 1865-1870
        • Bitton A.
        • Peppercorn M.A.
        • Antonioli D.A.
        • Niles J.L.
        • Shah S.
        • Bousvaros A.
        • et al.
        Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis.
        Gastroenterology. 2001; 120: 13-20
        • Azad S.
        • Sood N.
        • Sood A.
        Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study.
        Saudi J Gastroenterol. 2011; 17: 194-198
        • Bessissow T.
        • Lemmens B.
        • Ferrante M.
        • Bisschops R.
        • Van Steen K.
        • Geboes K.
        • et al.
        Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing.
        Am J Gastroenterol. 2012; 107: 1684-1692
        • Frøslie K.F.
        • Jahnsen J.
        • Moum B.A.
        • Vatn M.H.
        • IBSEN Group
        Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.
        Gastroenterology. 2007; 133: 412-422
        • Colombel J.F.
        • Rutgeerts P.
        • Reinisch W.
        • Esser D.
        • Wang Y.
        • Lang Y.
        • et al.
        Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
        Gastroenterology. 2011; 141: 1194-1201
        • Meucci G.
        • Fasoli R.
        • Saibeni S.
        • Valpiani D.
        • Gullotta R.
        • Colombo E.
        • et al.
        Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study.
        Inflamm Bowel Dis. 2012; 18: 1006-1010
        • Peyrin-Biroulet L.
        • Ferrante M.
        • Magro F.
        • Campbell S.
        • Franchimont D.
        • Fidder H.
        • et al.
        Results from the 2nd scientific workshop of the ECCO (I): impact of mucosal healing on the course of inflammatory bowel disease.
        J Crohn’s Colitis. 2011; 5: 477-483
        • Baars J.E.
        • Nuij V.J.
        • Oldenburg B.
        • Kuipers E.J.
        • van der Woude C.J.
        Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation.
        Inflamm Bowel Dis. 2012; 18: 1634-1640
        • Bryant R.V.
        • Winer S.
        • Travis S.P.
        • Riddell R.H.
        Systematic review: histological remission in inflammatory bowel disease. Is “complete” remission the new treatment paradigm? An IOIBD initiative.
        J Crohn’s Colitis. 2014; 8: 1582-1597
        • Riley S.A.
        • Mani V.
        • Goodman M.J.
        • Dutt S.
        • Herd M.E.
        Microscopic activity in ulcerative colitis: what does it mean?.
        Gut. 1991; 32: 174-178
        • Hefti M.M.
        • Chessin D.B.
        • Harpaz N.H.
        • Steinhagen R.M.
        • Ullman T.A.
        Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis.
        Dis Colon Rectum. 2009; 52: 193-197
        • Gupta R.B.
        • Harpaz N.
        • Itzkowitz S.
        • Hossain S.
        • Matula S.
        • Kornbluth A.
        • et al.
        Histologic inflammation is a risk factor for progression to Colorectal Neoplasia in ulcerative colitis: a cohort study.
        Gastroenterology. 2007; 133: 1099-1105
        • Rutter M.
        • Saunders B.
        • Wilkinson K.
        • Rumbles S.
        • Schofield G.
        • Kamm M.A.
        • et al.
        Severity of inflammation is a risk factor for Colorectal Neoplasia in ulcerative colitis.
        Gastroenterology. 2004; 126: 451-459
        • Marchal Bressenot A.
        • Riddell R.H.
        • Boulagnon-Rombi C.
        • Reinisch W.
        • Danese S.
        • Schreiber S.
        • et al.
        Review article: the histological assessment of disease activity in ulcerative colitis.
        Aliment Pharmacol Ther. 2015; 42: 957-967
        • Truelove S.C.
        Treatment of ulcerative colitis with local hydrocortisone.
        Br Med J. 1956; 2: 1267-1272
        • Geboes K.
        • Riddell R.
        • Ost A.
        • et al.
        A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.
        Gut. 2000; 47: 404-409
        • Jauregui-Amezaga A.
        • Geerits A.
        • Yannick D.
        • et al.
        A simplified Geboes score for ulcerative colitis.
        J Crohns Colitis. 2017; 11: 305-313
        • Theede K.
        • Holck S.
        • Ibsen P.
        • et al.
        Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis.
        Inflamm Bowel Dis. 2016; 22: 1042-1048
        • Riley S.A.
        • Mani V.
        • Goodman M.J.
        • Lucas S.
        Why do patients with ulcerative colitis relapse?.
        Gut. 1990; 31: 179-183
        • Patil D.T.
        • Moss A.C.
        • Odze R.D.
        Role of histologic inflammation in the natural history of ulcerative colitis.
        Gastrointest Endosc Clin N Am. 2016; 26: 629-640
        • Magro F.
        • Langner C.
        • Driessen A.
        • Ensari A.
        • Geboes K.
        • Mantzaris G.J.
        • et al.
        European consensus on the histopathology of inflammatory bowel disease.
        J Crohn’s Colitis. 2013; 7: 827-851
        • Zenlea T.
        • Yee E.U.
        • Rosenberg L.
        • Boyle M.
        • Nanda K.S.
        • Wolf J.L.
        • et al.
        Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study.
        Am J Gastroenterol. 2016; 111: 685-690
        • Bryant R.V.
        • Burger D.C.
        • Delo J.
        • Walsh A.J.
        • Thomas S.
        • von Herbay A.
        • et al.
        Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.
        Gut. 2016; 65: 408-414
        • Zezos P.
        • Patsiaoura K.
        • Nakos A.
        • Mpoumponaris A.
        • Vassiliadis T.
        • Giouleme O.
        • et al.
        Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy.
        Colorectal Dis. 2014; 16: O420-O430
        • Jauregui-Amezaga A.
        • López-Cerón M.
        • Aceituno M.
        • Jimeno M.
        • Rodríguez de Miguel C.
        • Pinó-Donnay S.
        • et al.
        Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis.
        Inflamm Bowel Dis. 2014; 20: 1187-1193
        • Zittan E.
        • Kelly O.B.
        • Kirsch R.
        • Milgrom R.
        • Burns J.
        • Nguyen G.C.
        • et al.
        Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn’s disease.
        Inflamm Bowel Dis. 2016; 22: 623-630
        • Mosli M.H.
        • Zou G.
        • Garg S.K.
        • Feagan S.G.
        • MacDonald J.K.
        • Chande N.
        • et al.
        C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis.
        Am J Gastroenterol. 2015; 110: 802-819

      Linked Article

      • Technological advances for improving adenoma detection rates: The changing face of colonoscopy
        Digestive and Liver DiseaseVol. 49Issue 7
        • Preview
          Worldwide, colorectal cancer is the third commonest cancer. Over 90% follow an adenoma-to-cancer sequence over many years. Colonoscopy is the gold standard method for cancer screening and early adenoma detection. However, considerable variation exists between endoscopists’ detection rates. This review considers the effects of different endoscopic techniques on adenoma detection. Two areas of technological interest were considered: (1) optical technologies and (2) mechanical technologies. Optical solutions, including FICE, NBI, i-SCAN and high definition colonoscopy showed mixed results.
        • Full-Text
        • PDF
      • Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the “ultra-deep” remission?
        Digestive and Liver DiseaseVol. 49Issue 12
        • Preview
          For many decades, the treatment goal in ulcerative colitis (UC) has been clinical remission, defined as a complete resolution of symptoms. Though it is still not standard of care, in recent years, medical treatment has also focused on mucosal healing as an important endpoint, together with clinical remission. However, it has been reported that up to 40% of patients have persistent histologic inflammatory activity despite having achieved clinical and endoscopic remission [1] and that histologic activity has been associated with a greater risk of clinical relapse, colectomy and dysplasia [2].
        • Full-Text
        • PDF
      • Is histologic remission in ulcerative colitis ready for prime time?
        Digestive and Liver DiseaseVol. 49Issue 12
        • Preview
          The management of inflammatory bowel disease (IBD) is based increasingly on the objective assessment of inflammation and mucosal integrity. It has been shown that macroscopic improvement of the mucosa indicates a better outcome of the disease, both in ulcerative colitis (UC) and in Crohn’s disease, thus highlighting the role of endoscopy in monitoring disease activity in IBD. In UC, mucosal healing based on endoscopic assessment is associated with decreasing relapse rates, hospitalization rates, and the need for surgery, and it is now becoming an end point of therapy.
        • Full-Text
        • PDF